Wochenschr. 2019 May;131(Suppl 1):151-163. German. doi: 10.1007/s00508-018-1425-x. PMID: 30980144.
5. Watanabe K, Sato E, Mishima E, et al. What's New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent Advances. Int J Mol Sci. 2022 Dec 29;24(1):570. doi: 10.3390/ijms24010570. PMID: 36614011.
6. Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022 Nov 19;400(10365):1788-1801. doi: 10.1016/S0140-6736(22)02074-8. Epub 2022 Nov 6. PMID: 36351458; PMCID: PMC7613836.
7. Georgianos PI, Vaios V, Roumeliotis S, et al. Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease. J Pers Med. 2022 Feb 6;12(2):223. doi: 10.3390/jpm12020223. PMID: 35207711; PMCID: PMC8874759.
8. Zhou G, Johansson U, Peng XR, et al. An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db/db mice. Am J Transl Res. 2016 Mar 15;8(3):1339-54. PMID: 27186263; PMCID: PMC4859623.
9. Liu WY, Yu SQ. [Research progress on the cardiorenal protection of non-steroid mineralocorticoid receptor antagonists in patients with chronic kidney disease]. Sheng Li Xue Bao. 2022 Dec 25;74(6):1023-1030. Chinese. PMID: 36594390.
10. Folkerts K, Millier A, Smela B, et al. Real-world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease. J Nephrol. 2022 Nov 23. doi: 10.1007/s40620-022-01492-w. Epub ahead of print. PMID: 36422853.
11. Epstein M. Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present. Am J Nephrol 2021;52:209-216. doi: 10.1159/000515622
12. Georgianos PI, Agarwal R. The non-steroidal MRA finerenone in cardiorenal medicine: a state-of-the-art review of the literature. Am J Hypertens. 2022 Nov 4:hpac124. doi: 10.1093/ajh/hpac124. Epub ahead of print. PMID: 36331811.
13. Goulooze SC, Heerspink HJL, van Noort M, et al. Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD. Clin Pharmacokinet. 2022 Jul;61(7):1013-1025. doi: 10.1007/s40262-022-01124-3. Epub 2022 May 5. PMID: 35508594; PMCID: PMC9287422.
14. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219-2229. doi: 10.1056/NEJMoa2025845.
15. Bakris GL, Ruilope LM, Anker SD, et al. FIDELIO-DKD and FIGARO-DKD Investigators. A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. Kidney Int. 2023 Jan;103(1):196-206. doi: 10.1016/j.kint.2022. 08. 040. Epub 2022 Oct 28. PMID: 36367466.
16. A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease (FIND-CKD). Available from: https://beta.clinicaltrials.gov/study/NCT05047263
17. Gay HC, Yu J, Persell S, et al. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Prescribing in Patients With Diabetes Mellitus With and Without Cardiovascular Disease.Am J Cardiol. 2023 Feb 15;189:121-130. doi: 10.1016/j.amjcard.2022. 10. 041. Epub 2022 Nov 22.PMID: 3642419
18. Zhang Y, Jiang L, Wang J, Wang T, et al. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.Cardiovasc Diabetol. 2022 Nov 5;21(1):232. doi: 10.1186/s12933-022-01676-5.
19. Giugliano D, Longo M, Signoriello S, et al. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.Cardiovasc Diabetol. 2022 Mar 16;21(1):42. doi: 10.1186/s12933-022-01474-z.
20. Schrier RW, Gurevich AK, Cadnapaphornchai MA. Pathogenesis and management of sodium and water retention in cardiac failure and cirrhosis.Semin Nephrol. 2001 Mar;21(2):157-72
21. Zelnick LR, Shlipak MG, Soliman EZ, et al. Prediction of Incident Atrial Fibrillation in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort Study. Clin J Am Soc Nephrol. 2021 Jul;16(7):1015-1024.
22. Arvid Engström, Viktor Wintzell, Mads Melbye, et al.: Sodium-Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study. Diabetes Care. 2023 Feb 1;46(2):351-360. doi: 10.2337/dc22-0714.
23. Jennifer B Green, Amy K Mottl, George Bakris, et al. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using an UACR Endpoint study (CONFIDENCE)Nephrol Dial Transplant. 2022 Jun 14;gfac198. doi: 10.1093/ndt/gfac198. Online ahead of print.